|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010802,
umls-concept:C0021747,
umls-concept:C0023474,
umls-concept:C0030705,
umls-concept:C0205195,
umls-concept:C0205197,
umls-concept:C0205263,
umls-concept:C0205269,
umls-concept:C0332173,
umls-concept:C0871261,
umls-concept:C0935989,
umls-concept:C0939537,
umls-concept:C1415900,
umls-concept:C1515021,
umls-concept:C1521991,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-20
|
|
pubmed:abstractText |
This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-? 2a to Imatinib mesylate (IM) 600mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1(+) BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFN?2a to IM600 is feasible, and able to overcome resistance within this context.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
pubmed-author:ChabaneKaddourK,
pubmed-author:CharbonnierAudeA,
pubmed-author:GuerciAgnèsA,
pubmed-author:HayetteSandrineS,
pubmed-author:LegrosLaurenceL,
pubmed-author:MagaudJean-PierreJP,
pubmed-author:MaloiselFrédéricF,
pubmed-author:MichalletMauricetteM,
pubmed-author:NicoliniFranck EFE,
pubmed-author:PailletCaroleC,
pubmed-author:PivotChristineC,
pubmed-author:PrébetThomasT,
pubmed-author:Rigal-HuguetFrançoiseF,
pubmed-author:RousselotPhilippeP,
pubmed-author:TulliezMichelM
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
80-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20605207-Adult,
pubmed-meshheading:20605207-Antineoplastic Agents,
pubmed-meshheading:20605207-Humans,
pubmed-meshheading:20605207-Interferon-alpha,
pubmed-meshheading:20605207-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:20605207-Middle Aged,
pubmed-meshheading:20605207-Piperazines,
pubmed-meshheading:20605207-Polyethylene Glycols,
pubmed-meshheading:20605207-Pyrimidines,
pubmed-meshheading:20605207-Recombinant Proteins,
pubmed-meshheading:20605207-Remission Induction
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Pegylated IFN-?2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
|
|
pubmed:affiliation |
Département d'hématologie clinique, hôpital Edouard Herriot, Lyon, France. franck-emmanuel.nicolini@chu-lyon.fr
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
